Stockpolly
Search
COEP · NASDAQ · Software - Services

Coeptis Therapeutics (COEP)

Nasdaq-listed Coeptis developed cell therapy assets before its Z Squared merger.

$10.99
At close−1.03 (−8.57%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000102
Cost of revenue000000000002
Gross profit00000000010−1
843322453340
Research & development511010001000
322212442210
Selling & marketing000000000000
General & administrative322212442210
Other expenses000000000030
Operating income−8−4−3−3−2−2−4−5−2−2−4−14
20000−1100000
Interest income000000000000
Interest expense000000000000
Other non-operating income−200001−100−100
Income before tax−6−4−3−3−2−3−3−4−3−2−4−14
Income tax expense000000000000
Net income from continuing operations−6−4−3−3−2−3−3−4−3−2−4−14
Net income−6−4−3−3−2−2−3−4−3−2−4−14
EPS, basic−$0.23−$0.11−$0.08−$0.08−$0.05−$1.01−$0.99−$0.95−$0.58−$0.29−$0.65−$0.28
EPS, diluted−$0.23−$0.11−$0.08−$0.08−$0.05−$1.01−$0.99−$0.95−$0.58−$0.29−$0.65−$0.28
Weighted average shares, basic273536384023454650
Weighted average shares, diluted273536384023454650
EBITDA−6−4−3−3−1−3−3−4−3−1−4−14
Depreciation & amortization000000000000
EBIT−6−4−3−3−2−3−3−4−3−1−40